VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Large Decline in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 11,105 shares, a decline of 55.8% from the December 15th total of 25,097 shares. Based on an average daily volume of 27,543 shares, the short-interest ratio is presently 0.4 days. Approximately 0.4% of the shares of the company are short sold. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 27,543 shares, the short-interest ratio is presently 0.4 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.23% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VivoSim Labs in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, VivoSim Labs currently has an average rating of “Sell”.

VivoSim Labs Stock Performance

Shares of VIVS opened at $2.01 on Thursday. The company has a 50-day simple moving average of $2.11 and a 200-day simple moving average of $2.33. VivoSim Labs has a 52 week low of $1.41 and a 52 week high of $21.96. The firm has a market capitalization of $5.25 million, a P/E ratio of -0.46 and a beta of 1.18.

VivoSim Labs (NASDAQ:VIVS) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.98) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.